Tempest Therapeutics, Inc. Share Price
TPSTTempest Therapeutics, Inc. Stock Performance
Open $1.30 | Prev. Close $1.25 | Circuit Range N/A |
Day Range $1.29 - $1.30 | Year Range $1.27 - $12.06 | Volume 573 |
Average Traded $1.29 |
Tempest Therapeutics, Inc. Share Price Chart
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Tempest Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
10-Jun-26 | $1.30 | $1.29 | +0.00% |
10-Jun-26 | $1.30 | $1.29 | +1.57% |
08-Jun-26 | $1.28 | $1.27 | -0.78% |
05-Jun-26 | $1.28 | $1.28 | -1.92% |
04-Jun-26 | $1.29 | $1.30 | +0.77% |
03-Jun-26 | $1.29 | $1.29 | -1.52% |
02-Jun-26 | $1.37 | $1.31 | -10.85% |